3SOF

On it's way to 20.

http://biz.yahoo.com/prnews/061228/cnth005.html?.v=8

This is a rare opportunity. I think it is going much higher.......buying more again tomorrow.

Added more today. I think it is going much higher.

Take the ride....It is going much higher.

http://moneycentral.hoovers.com/global/msn/factsheet.xhtml?COID=154720

http://biz.yahoo.com/prnews/061214/lnth005.html?.v=33

Subject: YOU DA MAN TEST



YOU DA MAN TEST...

1. In the company of females, intercourse should be referred to as:
   A. Lovemaking
   B. Screwing
   C. Taking the pigskin bus to tuna town.

2. You should make love to a woman for the first time only after you've both shared:
   A. Your views about what you expect from a sexual relationship
   B. Your blood-test results
   C. Five tequila slammers

3. You time your orgasm so that:
   A. Your partner climaxes first.
   B. You both climax simultaneously.
   C. You don't miss Sports Center

4. Passionate, spontaneous sex on the kitchen floor is:
   A. Healthy, creative love-play
   B. Not the sort of thing your wife/girlfriend would agree to
   C. Not the sort of thing your wife/girlfriend need to ever find out about.

5. Spending the whole night cuddling a woman you've just had sex with is:
   A. The best part of the experience
   B. The second best part of the experience
   C. $100 extra

6. You think today's sensitive, caring man is:
   A. A myth
   B. An oxymoron
   C. A Moron

7. Foreplay is to sex as:
   A. Appetizer is to entree
   B. Primer is to paint
   C. A long line is to an amusement park ride

8. Which of the following are you most likely to find yourself saying at the end of a relationship?
   A. "I hope we can still be friends"
   B. "I'm not in right now, please leave a message at the beep."
   C. "Welcome to Dumpsville, population: YOU."

9. A woman who is uncomfortable watching you masturbate:
   A. Probably needs a little more time before she can cope with the intimacy.
   B. Is uptight and a waste of time
   C. Shouldn't have sat next to you on the bus in the first place.


EVALUATING RESULTS:

If you answered "A" more than 7 times, check your pants to make sure you ARE a male!

If you answered "B" more than 7 times, check into therapy, you're a little confused.

If you answered "C" more than 7 times, "YOU DA MAN!"

> Ever spoken and wished that you could take the words back...or that

> you could crawl into a hole? Here are a few people who do....

>

>

> I walked into a hair salon with my husband and three kids in tow and

> asked loudly, "How much do you charge for a shampoo and a blow job?" I

> turned around and walked back out and never went back. My husband

> didn't say a word... he knew better. Melinda Lowe, 39, Seguin, TX

>

> ==================

>

> I was at the golf store comparing different kinds of golf balls. I was

> unhappy with the women's type I had been using. After browsing for

> several minutes, I was approached by one of the good-looking gentlemen

> who works at the store. He asked if he could help me. Without

> thinking, I looked at him and said, "I think I like playing with men's

> balls." Colleen Collins, 31, Ferndale, MI

>

> ===================

>

> Nuts about You

>

> My sister and I were at the mall and passed by a store that sold a

> variety of nuts. As we were looking at the display case, the boy

> behind the counter asked if we needed any help.

>

> I replied, "No, I'm just looking at your nuts."

>

> My sister started to laugh hysterically, the boy grinned, and I turned

> beet-red and walked away. To this day, my sister has never let me

> forget. Faye Emerick, 34, Ellerslie, MD

>

> ===================

>

> While in line at the bank one afternoon, my toddler decided to release

> some pent-up energy and ran amok. I was finally able to grab hold of

> her after receiving looks of disgust and annoyance from other patrons.

> I told her that

> if she did not start behaving "right now" she would be punished.

>

> To my horror, she looked me in the eye and said in a voice just as

> threatening, "If you don't let me go right now, I will tell Grandma

> that I saw you kissing Daddy's pee-pee last night!"

>

> The silence was deafening after this enlightening exchange. Even the

> tellers stopped what they were doing. I mustered up the last of my

> dignity and walked out of the bank with my daughter in tow. The last

> thing I heard when the door closed behind me were screams of laughter.

> Amy Richardson, Stafford, Virginia

>

> ====================

>

> A lady picked up several items at a discount store. When she finally

> got up to the checker, she learned that one of her items had no price

> tag. Imagine

> her embarrassment when the checker got on the intercom and boomed out for

> all the store to hear, "PRICE CHECK ON LANE THIRTEEN, TAMPAX SUPER SIZE."

>

> That was bad enough, but somebody at the rear of the store apparently

> misunderstood the word "Tampax" for "THUMBTACKS." In a business-like

> tone, a voice boomed back over the intercom.

>

> "DO YOU WANT THE KIND YOU PUSH IN WITH YOUR THUMB OR THE KIND YOU

> POUND IN WITH A HAMMER?" Diane E. Amov

> ===================

>

> Have you ever asked your child a question too many times? My

> three-year-old son had a lot of problems with potty training and I was

> on him constantly. One day we stopped at Taco Bell for a quick lunch

> in between errands. It was

> very busy, with a full dining room. While enjoying my taco, I smelled

> something funny, so of course I checked my seven-month-old daughter, and

> she

> was clean.

>

> Then I realized that Danny had not asked to go potty in a while, so I

> asked him if he needed to go, and he said "No."

>

> I kept thinking, "Oh Lord, that child has had an accident, and I don't

> have any clothes with me." Then I said, "Danny, are you SURE you

> didn't have an accident?"

>

> "No," he replied.

>

> I just KNEW that he must have had an accident, because the smell was

> getting worse. Soooooo! I asked one more time, "Danny, did you have an

> accident?"

>

> This time he jumped up, yanked down his pants, bent over and spread

> his cheeks and yelled. "SEE MOM, IT'S JUST FARTS!!"

>

> While 30 people nearly choked to death on their tacos laughing, he

> calmly pulled up his pants and sat down.

>

> An old couple made me feel better by thanking me for the best laugh

> they'd ever had! =================

>

> This had most of the state of Michigan laughing for 2 days and a very

> embarrassed female news anchor who will, in the future, likely think

> before she speaks. What happens when you predict snow but don't get

> any....a true story...

>

> We had a female news anchor who, the day after it was supposed to have

> snowed and didn't, turned to the weatherman and asked: "So Bob,

> where's that 8 inches you promised me last night?"

>

> Not only did HE have to leave the set, but half the crew did too they

> were laughing so hard!

Sherlock Holmes and Dr Watson go camping, and pitch their tent under the stars.

During the night, Holmes wakes his companion and says: "Watson, look up at the stars, and tell me what you deduce."

Watson says: "I see millions of stars, and even if a few of those have planets, it's quite likely there are some planets like Earth, and if there are a few planets like Earth out there, there might also be life."

Holmes replies: "Watson, you idiot. Somebody stole our tent ..."

May be a big week for ELN if the data goes through. It could get bought out just as well at this low price.

Biogen Idec (nasdaq: BIIB - news - people ) said it will cut its workforce by 17% by the end of the year; that means some 650 workers will be chopped worldwide in order to save $200 million to $300 million in expenses. The biotechnology firm expects to take a pre-tax charge of between $30 million to $40 million related to severance and associated staff restructuring costs. Biogen Idec and partner Elan (nyse: ELN - news - people ) halted sales of multiple sclerosis drug Tysabri last February after reports of a rare and potentially fatal central nervous system disease in patients. Data related to a completed safety review for Tysabri is expected to be handed over to the FDA by Sept. 21.

http://www.insidercow.com/

DJ ) 09/01 01:51AM DJ Biogen Idec To Seek Stronger Warning Label For MS Drug
CAMBRIDGE, Mass. (AP)--Biogen Idec Inc. will ask federal regulators to allow
it to resume sales of a multiple sclerosis drug linked to a brain disease with
additional warning labels, the company's CEO said in an interview.
James Mullen said Wednesday that Biogen Idec will likely recommend that
Tysabri include warnings about three cases of an often-fatal brain disease
that were confirmed after clinical trials of the drug, which was withdrawn
from the market Feb. 28 despite hopes that it would become an important new
tool in treating MS.
Mullen said the revised label that the company will propose to the U.S. Food
and Drug Administration also will warn about risks for patients who have weak
immune systems and therefore could be more susceptible to contracting the
disease, called progressive multifocal leukoencephalopathy, or PML.
However, Mullen said the label language his company will suggest to FDA when
it seeks permission to resume marketing Tysabri will acknowledge that
scientists don't yet understand precisely how the bioengineered drug put the
three patients who contracted PML at risk of contracting the rare disease. Two
of those patients died.
"I think it's important for us to not overstate what we know," Mullen,
Biogen Idec's chief executive and president, said in an interview with The
Associated Press at the company's Cambridge headquarters. "We want to be
concrete about what we know and what we don't know."
Mullen said Biogen Idec and its Irish partner on Tysabri, Elan Corp., plan
to submit findings from their review of the drug's safety to the FDA by the
end of September.
The companies had previously said the report would be submitted sometime in
the fall so the FDA could review whether Tysabri can safely return to the
market. Some industry analysts have said strong warnings on Tysabri's label
could ruin the drug's chances of becoming a commercial success.
Mullen said it is "highly unlikely" the FDA will complete its own review by
year's end, but he said the regulators are "interested in a thorough but
expeditious review of determining whether this can brought back to the market
in the near future or not."
FDA spokeswoman Lenore Gelb declined to comment Wednesday.
Biogen Idec and Elan said Aug. 9 that more than 2,000 patients with multiple
sclerosis who took Tysabri in clinical trials had been screened for PML as
part of the companies' safety review, but no new cases were found.
The companies are close to finishing a similar review of about 1,500 people
who took Tysabri in clinical trials to test its effectiveness in treating
Crohn's disease and rheumatoid arthritis.
After reviewing one year of data from planned two-year trials, federal
regulators in November approved Tysabri for sale to the 350,000 American
sufferers of MS, a debilitating and incurable disease in which the body's
immune system turns rebellious, attacking, inflaming and damaging its own
nerve tissue.
The drug was withdrawn about three months after its approval, causing Biogen
shares to plunge more than 42% the day of the announcement while Elan's stock
fell 70%.
"We hope there is a pathway back to the market," Mullen said. "We think that
unless we see some new surprises, that the risk-benefit profile for this
product certainly warrants it being used for MS.
"We've got probably hundreds of letters from patients saying, 'Tysabri
changed my life. I've got no other options. I'll sign whatever waiver I need
to get access to this product."'

DJ ) 09/01 01:51AM DJ Biogen Idec To Seek Stronger Warning Label For MS Drug
CAMBRIDGE, Mass. (AP)--Biogen Idec Inc. will ask federal regulators to allow
it to resume sales of a multiple sclerosis drug linked to a brain disease with
additional warning labels, the company's CEO said in an interview.
James Mullen said Wednesday that Biogen Idec will likely recommend that
Tysabri include warnings about three cases of an often-fatal brain disease
that were confirmed after clinical trials of the drug, which was withdrawn
from the market Feb. 28 despite hopes that it would become an important new
tool in treating MS.
Mullen said the revised label that the company will propose to the U.S. Food
and Drug Administration also will warn about risks for patients who have weak
immune systems and therefore could be more susceptible to contracting the
disease, called progressive multifocal leukoencephalopathy, or PML.
However, Mullen said the label language his company will suggest to FDA when
it seeks permission to resume marketing Tysabri will acknowledge that
scientists don't yet understand precisely how the bioengineered drug put the
three patients who contracted PML at risk of contracting the rare disease. Two
of those patients died.
"I think it's important for us to not overstate what we know," Mullen,
Biogen Idec's chief executive and president, said in an interview with The
Associated Press at the company's Cambridge headquarters. "We want to be
concrete about what we know and what we don't know."
Mullen said Biogen Idec and its Irish partner on Tysabri, Elan Corp., plan
to submit findings from their review of the drug's safety to the FDA by the
end of September.
The companies had previously said the report would be submitted sometime in
the fall so the FDA could review whether Tysabri can safely return to the
market. Some industry analysts have said strong warnings on Tysabri's label
could ruin the drug's chances of becoming a commercial success.
Mullen said it is "highly unlikely" the FDA will complete its own review by
year's end, but he said the regulators are "interested in a thorough but
expeditious review of determining whether this can brought back to the market
in the near future or not."
FDA spokeswoman Lenore Gelb declined to comment Wednesday.
Biogen Idec and Elan said Aug. 9 that more than 2,000 patients with multiple
sclerosis who took Tysabri in clinical trials had been screened for PML as
part of the companies' safety review, but no new cases were found.
The companies are close to finishing a similar review of about 1,500 people
who took Tysabri in clinical trials to test its effectiveness in treating
Crohn's disease and rheumatoid arthritis.
After reviewing one year of data from planned two-year trials, federal
regulators in November approved Tysabri for sale to the 350,000 American
sufferers of MS, a debilitating and incurable disease in which the body's
immune system turns rebellious, attacking, inflaming and damaging its own
nerve tissue.
The drug was withdrawn about three months after its approval, causing Biogen
shares to plunge more than 42% the day of the announcement while Elan's stock
fell 70%.
"We hope there is a pathway back to the market," Mullen said. "We think that
unless we see some new surprises, that the risk-benefit profile for this
product certainly warrants it being used for MS.
"We've got probably hundreds of letters from patients saying, 'Tysabri
changed my life. I've got no other options. I'll sign whatever waiver I need
to get access to this product."'